111P mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers.

MLA

Crook, T., et al. “111P MTOR Inhibitors in Combination Regimens Guided by Encyclopedic Tumour Analysis Show Superior Outcomes Compared to Monotherapy in Refractory Cancers.” Annals of Oncology, vol. 30, Nov. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdz413.115.

APA

Crook, T., Vaid, A., Limaye, S., Page, R., Patil, D., Akolkar, D., Datta, V., Ghaisas, A., Patil, R., Singh, H., Srinivasan, A., Apurwa, S., & Datar, R. (2019). 111P mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers. Annals of Oncology, 30, N.PAG. https://doi.org/10.1093/annonc/mdz413.115

Chicago

Crook, T, A Vaid, S Limaye, R Page, D Patil, D Akolkar, V Datta, et al. 2019. “111P MTOR Inhibitors in Combination Regimens Guided by Encyclopedic Tumour Analysis Show Superior Outcomes Compared to Monotherapy in Refractory Cancers.” Annals of Oncology 30 (November): N.PAG. doi:10.1093/annonc/mdz413.115.